ScreenerHero

BOLD Boundless Bio, Inc.

NAS · US · Healthcare · Biotechnology · boundlessbio.com
2.640USD+2.72%Mkt Cap: 60.05M $P/E: —

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap60.05M USD
Enterprise Value-14.17M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-58.20M USD
Revenue/Share—
Last Price2.640 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.62
PEG—
EV/EBITDA0.22
EV/Revenue—
P/S—
P/B0.88
EPS (TTM)-2.80
EPS (Forward)-0.98
52W Range
0.961076% of range3.164
52W High3.164 USD
52W Low0.9610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.99%
ROA-37.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.66M USD
CapEx (TTM)546.00K USD
FCF Margin—
FCF Yield-50.87%
Net Debt-72.63M USD
Net Debt/EBITDA1.13
Balance Sheet
Debt/Equity0.50
Current Ratio9.48
Quick Ratio9.35
Book Value/Sh2.94 USD
Cash/Share3.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Upside (mean)+51.5%
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.22.75M
Float16.08M
Insiders12.09%
Institutions67.26%
Short Interest
Short Ratio8.6d
Short % Float5.91%
Short % Out.3.57%
Shares Short811.96K
Short (prev mo.)689.44K
Technical
SMA 502.762 (-4.4%)
SMA 2001.797 (+46.9%)
Beta0.47
S&P 52W Chg16.45%
Avg Vol (30d)131.59K
Avg Vol (10d)178.37K
Technical Indicators
RSI (14)46.4
MACD-0.0451
MACD Signal-0.0276
MACD Hist.-0.0175
BB Upper2.962 USD
BB Middle2.711 USD
BB Lower2.459 USD
BB Width18.54%
ATR (14)0.1183 USD
Vol Ratio (20d)0.84x